VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | CAR T-cell therapy and BiTEs for myeloma

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, outlines results of the use of teclistamab, a BCMA x CD3 bispecific antibody in relapsed/refractory multiple myeloma (MM) patients, in addition to updates from KarMMa and CARTITUDE-1, evaluating the efficacy and safety of CAR T-cell therapies in MM. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter